Clabridine as Injection May Limit Relapsing MS Progression for Years

Clabridine as Injection May Limit Relapsing MS Progression for Years

312531

Clabridine as Injection May Limit Relapsing MS Progression for Years

Patients with relapsing multiple sclerosis (MS) treated with subcutaneous cladribine saw limited disease progression over a follow-up period of up to 20 years, especially with increased cumulative dosing, according to a recent study. Subcutaneous (SC) cladribine is administered as an under-the-skin injection. It is a formulation different from Mavenclad, marketed by EMD Serono (Merck KGaA outside of the U.S. and Canada), an oral formulation of cladribine that is approved to treat relapsing MS. The study,…

You must be logged in to read/download the full post.